
Wockhardt Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
Fri Apr 10 2026

Wockhardt (NSE: WOCKPHARMA) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With the stock at Rs 1,400 — against a 52-week high of Rs 1,820 and 1-year return of +32% — the Q4 FY26 results will be a pivotal event for investors.
Analyst estimates for Q4 FY26 revenue stand at Rs 780-840 Cr, with PAT expectations of Rs 5-25 Cr and margin projections of EBITDA 8-11%. This article covers the Wockhardt Q4 results 2026 date, earnings estimates, five key performance factors, five risks, analyst ratings, and investor FAQs.
Wockhardt Q4 Results 2026 Date
Get free investment predictions and live Q4 result alerts on Univest.
| Company | Results Date | Article |
| TCS | April 9, 2026 | Preview on Univest |
| Infosys | April 23, 2026 | Preview on Univest |
| Wockhardt | May 2026 (Expected) | This article |
Why This Quarter Matters
Wockhardt enters Q4 FY26 with expectations of 8-12% YoY revenue growth. Q4 determines full-year FY26 performance, sets FY27 estimate baselines, and triggers final dividend announcements. At a 1-year return of +32%, this quarter’s results and FY27 guidance will be critical for determining stock trajectory.
Wockhardt Q4 FY26 Earnings Estimates

Access premium SEBI-registered research on Univest.
| Metric | Q3 FY26 Actual | Q4 FY26 Estimate | Driver |
| Revenue | Rs 723 Cr | Rs 780-840 Cr | Volume + pricing |
| PAT | Rs -18 Cr | Rs 5-25 Cr | Operating leverage |
| Margin | EBITDA 8.4% | EBITDA 8-11% | Cost control |
| Key Growth Metric | Q3 trend | 8-12% YoY revenue growth | Management execution |
| Dividend Estimate | — | Nil expected | Board recommendation |
Screen Wockhardt fundamentals on Univest Screener.
5 Key Factors That Will Drive Wockhardt Q4 FY26 Performance
Revenue Momentum
Analysts expect Rs 780-840 Cr in Q4 FY26 revenue versus Rs 723 Cr in Q3. Q4 is seasonally important for the Pharma sector and the ability to convert the pipeline into recognised revenue will be the first performance test.
Margin Trajectory
Q4 FY26 margin expectations are EBITDA 8-11% versus EBITDA 8.4% in Q3. Input cost trends, employee expenses, and pricing power will determine whether the company can sustain or improve on Q3 levels.
PAT Quality
Net profit is estimated at Rs 5-25 Cr. Investors will assess whether PAT is driven by operational improvement or non-recurring items. A clean recurring profit print is most positively received by institutional investors.
Management Guidance for FY27
The most consequential output will be FY27 guidance — revenue growth bands, margin targets, and capex plans. Credible FY27 guidance carries significant weight for re-rating potential in the current macro environment.
Dividend Declaration
Wockhardt is expected to consider a final dividend of Nil expected. The quantum signals management’s confidence in free cash flow generation and sets expectations for FY27 capital allocation.
5 Risks to Watch in Wockhardt Q4 FY26
US Tariff and Macro Headwinds
The 26% US reciprocal tariff on Indian goods has created macro uncertainty. For Wockhardt, indirect impacts include FII outflows and earnings estimate cuts if global demand slows.
Earnings Miss Risk
If Wockhardt’s Q4 FY26 results miss estimates, the stock could correct sharply. Investors should monitor revenue versus Rs 780-840 Cr and PAT versus Rs 5-25 Cr as the two primary watchpoints.
FY27 Guidance Below Consensus
If FY27 guidance falls below Street expectations, the stock may decline even if Q4 numbers are in line. Forward guidance carries more weight than the reported quarter currently.
FII Outflow Continuation
FIIs sold Rs 22,000 crore in Indian equities in a single week following the tariff announcement. Continued selling creates headwinds for Wockhardt regardless of fundamentals.
Sector Regulatory Risk
The Pharma sector faces evolving regulatory frameworks. Policy changes that increase compliance costs or alter competitive dynamics could affect Wockhardt’s profitability.
Wockhardt Share Price and Analyst Ratings

Wockhardt is trading at Rs 1,400 as of early April 2026, against a 52-week high of Rs 1,820 and 52-week low of Rs 980. Market cap stands at Rs 12,800 Cr.
| Brokerage | Rating | Target Price | Thesis |
| MOFSL | Neutral | Rs 1,500 | UK + India turnaround; WCK5222 antibiotic |
| YES Securities | Buy | Rs 1,650 | Novel antibiotic pipeline; global licensing |
| JM Financial | Add | Rs 1,550 | Profitability inflection FY27 key catalyst |
| Emkay | Neutral | Rs 1,450 | High risk high reward; antibiotic pipeline |
Download the Univest iOS App or Univest Android App to track Wockhardt live and receive real-time Q4 result alerts.
Conclusion
Wockhardt Q4 FY26 results on May 2026 (Expected) will be a key event for Pharma sector investors. Analysts project PAT of Rs 5-25 Cr and revenue of Rs 780-840 Cr. At Rs 1,400 with analyst targets from Rs 1,450 to Rs 1,500, FY27 guidance will be the most critical post-results catalyst.
For more Q4 FY26 previews, visit Univest Blogs.
Frequently Asked Questions
What is the Wockhardt Q4 results 2026 date?
The Wockhardt Q4 results 2026 date is May 2026 (Expected). The board will meet to approve audited Q4 FY26 financials and consider a final dividend recommendation.
What is the Wockhardt Q4 FY26 PAT estimate?
Analysts estimate Wockhardt Q4 FY26 PAT at Rs 5-25 Cr, based on revenue of Rs 780-840 Cr and margin of EBITDA 8-11%.
What is Wockhardt’s share price ahead of Q4 results?
Wockhardt is trading at Rs 1,400. The 52-week high is Rs 1,820 and low is Rs 980. The 1-year return is +32% and market cap is Rs 12,800 Cr.
Will Wockhardt declare a dividend in Q4 FY26?
Wockhardt is expected to consider a final dividend of Nil expected at the Q4 FY26 board meeting on May 2026 (Expected).
Which analysts have a Buy rating on Wockhardt?
YES Securities (Buy, Rs 1,650), JM Financial (Add, Rs 1,550) have positive ratings heading into Q4 FY26.
What were Wockhardt Q3 FY26 results?
Wockhardt reported Q3 FY26 revenue of Rs 723 Cr and PAT of Rs -18 Cr, with margin at EBITDA 8.4%.
When do TCS and Infosys announce Q4 results 2026?
TCS declared Q4 FY26 results on April 9, 2026. Infosys Q4 FY26 results are scheduled for April 23, 2026. Read both previews on Univest Blogs.
Is Wockhardt a good investment ahead of Q4 results?
This depends on your risk appetite. Wockhardt has compelling long-term factors alongside genuine near-term risks. Consult a SEBI-registered financial advisor before investing.
Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only. All financial data and analyst estimates are sourced from publicly available information. Verify before investing. Consult a SEBI-registered advisor before making investment decisions.
Recent Article
UPL Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
Zee Entertainment Enterprises Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
Sun TV Network Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
Sapphire Foods India Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
Metro Brands Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
Related Posts
Trent Stock Surges 18% in 3 Weeks — Is Westside’s Parent the Next Big Retail Multibagger?
Piramal Enterprises Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
Tatva Chintan Surges 22% in 1 Month — Is This Green Chemistry IPO Gem Finally Making Good on Its Promise?
Why Is PNB Housing Finance Share Price Falling? Key Reasons & Share Price Target
SRF Quietly Rises 9% in 10 Days — Is India’s Fluorochemical King About to Re-Rate to Global Specialty Levels?

